Skip to main content
TipRanks
Go Ultimate75% OFF

Bio-Rad Laboratories (BIO) AI Stock Analysis

931 Followers
BIO

Bio-Rad Laboratories

(NYSE:BIO)

Select Model
Rating:71Outperform
Price Target:$420.00â–²(17.26% Upside)
Action:reiterated
Date:11/05/26

The score is primarily driven by solid financial quality (notably a conservative balance sheet) alongside improving TTM profitability and cash generation, but tempered by historically volatile earnings and uneven free-cash-flow momentum. Technicals add support with an uptrend and moderate momentum, while valuation is favorable due to a low P/E. The earnings call is a modest headwind given negative-to-flat revenue guidance and persistent Life Science/China and logistics pressures despite improving margins and reaffirmed cash-flow outlook.

Positive Factors
Conservative balance sheetBio-Rad’s low leverage and substantial equity base provide financial resilience and reduce refinancing risk. This structure gives management flexibility to continue investing in innovation, support operations through uneven demand, and pursue measured acquisitions without relying heavily on additional debt.
Negative Factors
Weak revenue outlookThe outlook indicates that overall demand remains fragile, particularly in Life Science, limiting near-term revenue visibility and operating leverage. Negative-to-flat growth also makes it harder to absorb fixed costs, sustain margin expansion, and build confidence that the recovery will persist.

Bio-Rad Laboratories Key Performance Indicators (KPIs)

Revenue by SegmentAnalyzes income from different business areas, highlighting which segments drive growth and profitability, and where the company might focus future efforts.

-$200.00M$0.00$200.00M$400.00M$600.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Clinical Diagnostics has become the stable growth engine—sequential recovery and ddPCR/Stilla momentum are real and underpin recent margin improvement—while Life Science remains a multiyear soft spot, hurt by China order timing, weak consumable pull‑through and lumpy process‑chromatography demand. Other Operations is effectively negligible/exit‑level, removing a minor revenue tail. Management’s restructuring and buyback should lift margins, but top‑line upside hinges on consumables recovery and China normalizing; guidance still allows modest contraction, so a durable revenue inflection isn’t yet guaranteed.

Data provided by:The Fly

Bio-Rad Laboratories (BIO) vs. SPDR S&P 500 ETF (SPY)

-30%-20%-10%0%10%20%30%BIO+13.10%SPY+13.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$9.63B
Dividend Yield
―
Average Volume (3M)
255.67K
Price to Earnings (P/E)
9.4
Beta (1Y)
0.81
Revenue Growth
1.38%
EPS Growth
―
Country
US
Employees
7,450
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Bio-Rad Laboratories Business Overview & Revenue Model

Company Description

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, an...

How the Company Makes Money

Bio-Rad makes money primarily by selling products and services across its two operating segments (Life Science and Clinical Diagnostics). Revenue is largely generated from (1) instrument sales (e.g., laboratory and diagnostic systems), which can be h...

Bio-Rad Laboratories Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-5.74%|Next Earnings Date:Feb 18, 2027
Earnings Call SentimentNeutral

The call conveyed cautious optimism. Bio-Rad highlighted a return to modest currency-neutral revenue growth, improving non-GAAP margins, strong ddPCR instrumentation, Diagnostics growth, product launches and ongoing restructuring and innovation initiatives. However, these positives were offset by declining total Life Science revenue, weak academic and government funding, China pricing pressure, logistics disruption, an expected fourth-quarter margin decline, negative-to-flat full-year revenue guidance and GAAP losses driven by restructuring and impairment charges. Management expects positive but not fully normalized growth in 2027.

Positive Updates

Return to Currency-Neutral Revenue Growth
Third-quarter revenue was approximately $656 million, up 0.5% on a reported basis and 0.7% on a currency-neutral basis versus the prior year. This was Bio-Rad's first quarter of currency-neutral growth in 2026.

Negative Updates

Modest Overall Revenue Growth
Although revenue returned to currency-neutral growth, the increase was only 0.5% on a reported basis and 0.7% on a currency-neutral basis, and management described the pace of growth as modest.

Company Guidance

Bio-Rad reaffirmed full year '26 currency-neutral revenue growth between minus 3% and plus 0.5%, with full year growth expected to be approximately at the midpoint of this range; Life Science segments currency-neutral revenue growth is expected to be between minus 3% and minus 1%, and Clinical Diagnostics segment's currency-neutral revenue growth between minus 3% and plus 1%. Q4 revenue is expected to ramp up 5% to 6% on a reported basis, full year non-GAAP gross margin is expected in the upper half of the guidance range of between 53% and 54%, and full year non-GAAP operating margin in the upper half of the guidance range of between 10% and 12%; Q4 SG&A is expected to be flat to Q3, R&D to step up $3 million sequentially, and depreciation and amortization to be approximately $40 million. Full year 2026 free cash flow is expected to be in the range of approximately $290 million to $340 million. Management is focused on driving towards positive growth rate in '27 and driving further margin expansion in '27; it estimated the National Healthcare Security Administration guidelines' revenue impact in the middle single-digit millions of dollars in 2027, expects logistics disruption to continue into 2027, and expects $30 million, $35 million in restructuring savings, with full realization starting in '28.

Bio-Rad Laboratories Financial Statement Overview

Summary

Strong balance sheet (low leverage, large equity base) supports resilience, while TTM results show a rebound in revenue growth and a return to profitability with healthy gross margins. The main constraint is multi-year volatility in earnings and uneven cash-flow momentum (recent FCF growth negative and cash conversion variability), which lowers confidence in durability.

Income Statement

62Positive

Balance Sheet

82Very Positive

Cash Flow

66Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.59B2.58B2.57B2.67B2.80B2.92B
Gross Profit1.33B1.34B1.38B1.43B1.57B1.64B
EBITDA1.48B1.21B-2.14B-654.80M-4.53B5.59B
Net Income1.02B759.90M-1.84B-637.32M-3.63B4.25B
Balance Sheet
Total Assets10.78B10.58B9.36B12.30B13.50B17.80B
Cash, Cash Equivalents and Short-Term Investments1.66B1.54B1.66B1.61B1.79B869.92M
Total Debt1.36B1.53B1.37B1.41B1.39B223.38M
Total Liabilities3.18B3.12B2.79B3.56B3.89B4.11B
Stockholders Equity7.60B7.45B6.57B8.74B9.62B13.69B
Cash Flow
Free Cash Flow329.10M374.60M266.20M218.26M80.29M535.72M
Operating Cash Flow468.10M532.20M455.20M374.94M194.45M669.46M
Investing Cash Flow-340.00M-189.70M-160.20M20.21M-1.21B-797.38M
Financing Cash Flow-70.20M-283.20M-218.80M-425.65M973.58M-55.43M

Bio-Rad Laboratories Technical Analysis

Technical Analysis SentimentNeutral
Last Price358.19

Price Trends

50DMA372.00Negative
100DMA354.89Positive
200DMA317.63Positive

Market Momentum

MACD-0.61Positive
RSI41.16Neutral
STOCH22.31Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIO, the sentiment is Neutral. The current price of 358.19 is below the 20-day moving average (MA) of 373.84, below the 50-day MA of 372.00, and above the 200-day MA of 317.63, indicating a neutral trend. The MACD of -0.61 indicates Positive momentum. The RSI at 41.16 is Neutral, neither overbought nor oversold. The STOCH value of 22.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BIO.

Bio-Rad Laboratories Risk Analysis

Bio-Rad Laboratories disclosed 28 risk factors in its most recent earnings report. Bio-Rad Laboratories reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk
1.Use of generative AI and other AI technologies presents risks and challenges due to the evolving nature of AI.Q4, 2024

Bio-Rad Laboratories Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

BIO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GKOSGKOS75Outperform$14.40B-83.03-24.91%―46.94%-89.79%
BIOBIO71Outperform$9.73B9.4114.07%―1.38%―
NEOGNEOG61Neutral$2.38B-43.11-2.68%―-0.33%94.64%
BRKRBRKR57Neutral$9.37B-55.94-5.15%0.33%2.16%-604.24%
CTKBCTKB53Neutral$745.47M-9.02-24.74%―5.50%-524.33%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
QTRXQTRX40Underperform$135.79M-1.21-42.99%―13.78%-1.29%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%BIOBRKRNEOGGKOSQTRXCTKBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BIO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BIOBio-Rad Laboratories358.1954.5817.98%
BRKRBruker Corporation61.3617.7140.56%
NEOGNeogen10.905.49101.48%
GKOSGlaukos Corp.243.25148.05155.51%
QTRXQuanterix2.86-3.05-51.61%
CTKBCytek Biosciences, Inc.5.700.499.40%

Bio-Rad Laboratories Corporate Events

Financial Disclosures

Bio-Rad Reports Third-Quarter Results and Improved Profitability

Positive
Nov 4, 2026

On November 4, 2026, Bio-Rad reported third-quarter net sales of $656.4 million, up 0.5% from $653.0 million a year earlier. Currency-neutral sales increased 0.7%, led by a 2.8% currency-neutral gain in Clinical Diagnostics, while Life Science sales...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026